Rezolute, Inc. — Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended June 30, 2020, not calendar-year 2019 Q4. Rezolute is a clinical-stage biopharmaceutical company with no commercial products or revenue. Its lead candidate, RZ358, was in Phase 2b development for congenital hyperinsulinism (CHI); RZ402, an oral candidate for diabetic macular edema (DME), was IND-ready. Per-share and share-count figures in the filing are retrospectively adjusted for the 1-for-50 reverse stock split effective October 9, 2020.
Key financial metrics
| Metric | FY2020 / June 30, 2020 | FY2019 / June 30, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $14.5 million | $19.1 million |
| General and administrative expense | $6.1 million | $6.9 million |
| Total operating expense / operating loss | $20.5 million | $25.9 million |
| Net loss | $20.3 million | $30.4 million |
| Net cash used in operating activities | $24.2 million | $15.3 million |
| Cash and cash equivalents | $10.0 million | $11.6 million |
| Working capital | $7.3 million | Not stated here |
| Total liabilities | $3.6 million | $10.5 million |
| Stockholders’ equity | $7.4 million | $1.8 million |
Margins are not meaningful because the company had no revenue. No conventional debt was reported at June 30, 2020; liabilities included $1.8 million payable to Xoma and $0.4 million of operating lease liabilities. The independent auditor issued an unqualified opinion on the financial statements.
Material changes versus the prior comparable period
- Net loss narrowed by $10.1 million, or 33%, primarily because FY2019 included $14.0 million of Xoma licensing expense and $5.0 million of interest expense related to converted notes. These reductions more than offset higher FY2020 clinical, compensation, and outside-service costs.
- R&D expense fell 24%, but clinical trial costs rose to $4.0 million from $0.04 million as the RIZE Phase 2b trial began. R&D compensation and benefits increased to $5.9 million from $2.6 million.
- Operating cash use increased by $8.9 million despite the lower net loss, chiefly reflecting cash payments against Xoma obligations and other working-capital movements.
- Cash decreased by $1.6 million during FY2020. Equity financings in July and August 2019 provided $22.6 million net proceeds.
Outlook, risks, contingencies, and unusual items
- Subsequent financing and runway: On October 9, 2020, the company completed a private placement for $41.0 million gross and approximately $37.6 million net, issuing approximately 2.5 million shares and warrants for 0.8 million shares. Management said cash at June 30 plus the financing proceeds should fund currently planned activities into the second half of FY2022. The financing triggered repayment of the remaining $1.8 million Xoma obligation.
- Clinical outlook: RIZE enrollment was paused in March 2020 because of COVID-19. At the filing date, management expected enrollment to recommence by the end of October 2020 and, if that occurred, completion in the second half of calendar 2021. RZ402’s IND filing was deferred; the company anticipated starting its clinical trial before the end of Q1 2021. These are forward-looking expectations, not assured outcomes.
- COVID-19: FY2020 financial results were not significantly affected, but trial enrollment, site initiation, access to healthcare facilities, operations, financing, and supply chains remained exposed to disruption and added cost. The duration and ultimate impact were uncertain.
- Funding and development risk: The company has a $147.2 million accumulated deficit, ongoing losses, no revenue, and expects continued operating losses and need for additional capital. Failure to obtain funding could require delays, reductions, partnering, or discontinuation of programs. Drug candidates remain subject to clinical, regulatory, manufacturing, and commercialization risks.
- Licensing obligations: Xoma may receive up to $197.0 million in RZ358 milestone payments plus royalties; the first milestone is linked to enrollment of the last patient in the ongoing Phase 2 study. ActiveSite may receive up to $46.5 million in milestones and 2% royalties for products using its PKI program; its first $1.0 million milestone is tied to RZ402 preclinical completion and IND submission. These are contingent obligations, not amounts currently payable in full.
- Governance and control: Handok and Genexine held approximately 34% and 31%, respectively, of outstanding shares as of September 30, 2020, giving them substantial influence. The company was seeking Nasdaq Capital Market listing but provided no assurance of success. The reverse split and post-year-end financing materially changed share counts and capital structure.
- Internal controls: Management concluded disclosure controls and internal control over financial reporting were not effective at June 30, 2020 due to a material weakness in segregation of duties and the risk of employee override. Remediation efforts were incomplete.
- Other items: The company discontinued AB101 development after Phase 1 top-line results indicated formulation adjustments were needed. It recognized a $23,000 impairment charge on patents. On September 15, 2020, it licensed products including RZ358 and RZ402 to Handok in South Korea; no milestone payments had yet been earned.
Most important facts for investors to verify
- Whether the October 2020 financing proceeds, Xoma repayment, and stated runway are reflected in subsequent cash balances and spending.
- Actual RIZE restart, enrollment progress, safety and efficacy data, and whether the projected study timeline remains achievable.
- RZ402 IND submission and Phase 1 start timing, along with any resulting ActiveSite milestone payment.
- Progress toward Nasdaq listing and the resulting effects of the reverse split, warrants, and new shares on liquidity and dilution.
- Whether management remediated the material weakness and improved disclosure controls.
- Potential limits on use of approximately $85.2 million of federal NOL carryforwards following ownership changes, which the company had not yet fully analyzed.